[{"id":"6c31d924-416a-4fac-90f3-4e9e04970c2d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04708470","created_at":"2021-01-19T20:51:59.772Z","updated_at":"2025-02-25T12:27:53.092Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers","source_id_and_acronym":"NCT04708470","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CD4","pipe":" | ","alterations":" PD-L1 negative","tags":["PD-L1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jingzhuda (entinostat) • bintrafusp alfa (M7824) • PDS01ADC"],"overall_status":"Recruiting","enrollment":" Enrollment 107","initiation":"Initiation: 10/05/2021","start_date":" 10/05/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-24"},{"id":"da2147db-6d4b-4bfe-ac5e-f6786f79f209","acronym":"","url":"https://clinicaltrials.gov/study/NCT05881265","created_at":"2023-05-31T15:05:36.513Z","updated_at":"2025-02-25T14:17:59.340Z","phase":"Phase 2","brief_title":"Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia","source_id_and_acronym":"NCT05881265","lead_sponsor":"Shanghai Jiao Tong University School of Medicine","biomarkers":" RARA • PML","pipe":"","alterations":" ","tags":["RARA • PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Epidaza (chidamide)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/15/2023","start_date":" 05/15/2023","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2025-02-18"},{"id":"2e071664-2674-4d6f-b1a9-33056e7adbe4","acronym":"","url":"https://clinicaltrials.gov/study/NCT02115282","created_at":"2021-01-17T17:34:12.805Z","updated_at":"2025-02-25T16:43:48.211Z","phase":"Phase 3","brief_title":"Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic","source_id_and_acronym":"NCT02115282","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR","pipe":"","alterations":" ","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e exemestane • Jingzhuda (entinostat) • goserelin acetate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 608","initiation":"Initiation: 03/29/2014","start_date":" 03/29/2014","primary_txt":" Primary completion: 05/05/2020","primary_completion_date":" 05/05/2020","study_txt":" Completion: 06/25/2025","study_completion_date":" 06/25/2025","last_update_posted":"2025-02-06"},{"id":"78abffa2-7b4c-493d-a391-404776dd9c0b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01038778","created_at":"2021-01-18T04:04:38.458Z","updated_at":"2025-02-25T16:58:23.955Z","phase":"Phase 1/2","brief_title":"Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer","source_id_and_acronym":"NCT01038778","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" mTOR","pipe":"","alterations":" ","tags":["mTOR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jingzhuda (entinostat) • Proleukin (aldesleukin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 10/29/2009","start_date":" 10/29/2009","primary_txt":" Primary completion: 05/22/2019","primary_completion_date":" 05/22/2019","study_txt":" Completion: 07/30/2025","study_completion_date":" 07/30/2025","last_update_posted":"2025-02-03"},{"id":"1bb717ea-4a5e-4f29-ac5a-fee115e523c2","acronym":"","url":"https://clinicaltrials.gov/study/NCT03179930","created_at":"2021-01-18T15:40:48.245Z","updated_at":"2025-02-25T16:06:23.103Z","phase":"Phase 2","brief_title":"Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas","source_id_and_acronym":"NCT03179930","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CTLA4","pipe":"","alterations":" ","tags":["CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Jingzhuda (entinostat)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 06/07/2017","start_date":" 06/07/2017","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2025-01-24"},{"id":"84edb0cb-23b4-41c9-a4af-3815707a7019","acronym":"","url":"https://clinicaltrials.gov/study/NCT05958719","created_at":"2025-02-26T07:45:46.896Z","updated_at":"2025-02-26T07:45:46.896Z","phase":"Phase 2","brief_title":"Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma","source_id_and_acronym":"NCT05958719","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital, China","biomarkers":" IFNG • IL6 • TNFA • IL10 • IFNA1","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • IL10 • IFNA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • prednisone • Epidaza (chidamide) • Duoenda (mitoxantrone liposomal)"],"overall_status":"Recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 03/02/2023","start_date":" 03/02/2023","primary_txt":" Primary completion: 12/30/2026","primary_completion_date":" 12/30/2026","study_txt":" Completion: 03/02/2027","study_completion_date":" 03/02/2027","last_update_posted":"2024-12-30"},{"id":"acc6da2f-38b7-4ab4-ba2e-48ab70259f4a","acronym":"","url":"https://clinicaltrials.gov/study/NCT06532552","created_at":"2025-02-26T13:41:40.179Z","updated_at":"2025-02-26T13:41:40.179Z","phase":"Phase 2","brief_title":"Comparison of VA (Venetoclax, Azacitidine), VACl (VA, Cladribine), VACh (VA, Chidamide), and Alternating VACl/VACh in Newly Diagnosed Acute Myeloid Leukemia","source_id_and_acronym":"NCT06532552","lead_sponsor":"The First Affiliated Hospital of Soochow University","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • Epidaza (chidamide) • cladribine"],"overall_status":"Recruiting","enrollment":" Enrollment 172","initiation":"Initiation: 07/29/2024","start_date":" 07/29/2024","primary_txt":" Primary completion: 08/01/2027","primary_completion_date":" 08/01/2027","study_txt":" Completion: 08/01/2028","study_completion_date":" 08/01/2028","last_update_posted":"2024-11-20"},{"id":"23a26ba2-c7b3-4108-b7df-8c971e5ceef9","acronym":"DEL Biomarker","url":"https://clinicaltrials.gov/study/NCT06652152","created_at":"2025-02-26T12:22:45.189Z","updated_at":"2025-02-26T12:22:45.189Z","phase":"","brief_title":"Mechanism Investigation of R-CHOP Regimen or Tucidinostat Plus R-CHOP (CR-CHOP) Regimen in the Treatment of BCL2/MYC Protein Double Expressor Lymphoma","source_id_and_acronym":"NCT06652152 - DEL Biomarker","lead_sponsor":"Ruijin Hospital","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • Epidaza (chidamide)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 10/30/2024","start_date":" 10/30/2024","primary_txt":" Primary completion: 05/30/2025","primary_completion_date":" 05/30/2025","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2024-10-22"},{"id":"c3e37946-e4b9-4544-a60c-995c415bbbe7","acronym":"","url":"https://clinicaltrials.gov/study/NCT06563778","created_at":"2025-02-26T10:28:05.577Z","updated_at":"2025-02-26T10:28:05.577Z","phase":"Phase 2","brief_title":"Chidamide+Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.","source_id_and_acronym":"NCT06563778","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" PD-1","pipe":"","alterations":" ","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e decitabine • Adcetris (brentuximab vedotin) • Epidaza (chidamide) • bendamustine"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 09/01/2024","start_date":" 09/01/2024","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2028","study_completion_date":" 09/01/2028","last_update_posted":"2024-08-21"},{"id":"01bb6da0-1295-4869-97f4-aac2478019c5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04674683","created_at":"2021-01-19T20:45:32.528Z","updated_at":"2025-02-25T14:29:47.853Z","phase":"Phase 3","brief_title":"Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma","source_id_and_acronym":"NCT04674683","lead_sponsor":"HUYABIO International, LLC.","biomarkers":" BRAF","pipe":" | ","alterations":" PD-L1 expression • BRAF mutation • PD-L1 negative","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRAF mutation • PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Epidaza (chidamide)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 450","initiation":"Initiation: 08/12/2021","start_date":" 08/12/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2024-06-24"},{"id":"576b9aae-2746-4ca3-a5a4-167bcd5465e4","acronym":"","url":"https://clinicaltrials.gov/study/NCT06393361","created_at":"2024-05-04T04:28:35.114Z","updated_at":"2024-07-02T16:34:27.321Z","phase":"Phase 2","brief_title":"Chidamide+Decitabine Plus Anti-PD-1 Antibody in PD-1 Inhibitor Failed Patients With Classical Hodgkin Lymphoma.","source_id_and_acronym":"NCT06393361","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" PD-1","pipe":"","alterations":" ","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • ifosfamide • etoposide IV • decitabine • pegylated liposomal doxorubicin • Adcetris (brentuximab vedotin) • Epidaza (chidamide)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 06/01/2024","start_date":" 06/01/2024","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-06-11"},{"id":"0fe10839-16f3-4ebf-97c8-7feb7f85fc90","acronym":"","url":"https://clinicaltrials.gov/study/NCT05083208","created_at":"2021-10-19T15:58:00.734Z","updated_at":"2024-07-02T16:35:05.553Z","phase":"Phase 1/2","brief_title":"PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma","source_id_and_acronym":"NCT05083208","lead_sponsor":"Henan Cancer Hospital","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive • ALK negative","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Epidaza (chidamide) • parsaclisib (INCB50465)"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 02/20/2022","start_date":" 02/20/2022","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-05-07"},{"id":"820e22ed-50fe-40f0-aa7c-051ded02330b","acronym":"CA209-117","url":"https://clinicaltrials.gov/study/NCT01928576","created_at":"2021-01-18T08:42:53.521Z","updated_at":"2025-02-25T14:34:17.894Z","phase":"Phase 2","brief_title":"Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.","source_id_and_acronym":"NCT01928576 - CA209-117","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" EGFR • KRAS • ALK","pipe":" | ","alterations":" EGFR mutation • EGFR exon 19 deletion • ALK positive • ALK rearrangement • EGFR wild-type • ALK wild-type • ALK translocation","tags":["EGFR • KRAS • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 19 deletion • ALK positive • ALK rearrangement • EGFR wild-type • ALK wild-type • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • azacitidine • Jingzhuda (entinostat) • Onureg (azacitidine oral)"],"overall_status":"Completed","enrollment":" Enrollment 143","initiation":"Initiation: 11/06/2013","start_date":" 11/06/2013","primary_txt":" Primary completion: 04/04/2023","primary_completion_date":" 04/04/2023","study_txt":" Completion: 04/04/2023","study_completion_date":" 04/04/2023","last_update_posted":"2024-05-03"},{"id":"052ff42c-445e-466e-9061-7503375beb53","acronym":"","url":"https://clinicaltrials.gov/study/NCT01349959","created_at":"2021-01-18T05:30:54.553Z","updated_at":"2024-07-02T16:35:11.296Z","phase":"Phase 2","brief_title":"Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer","source_id_and_acronym":"NCT01349959","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HR positive • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • Jingzhuda (entinostat)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 04/21/2011","start_date":" 04/21/2011","primary_txt":" Primary completion: 03/27/2014","primary_completion_date":" 03/27/2014","study_txt":" Completion: 03/07/2025","study_completion_date":" 03/07/2025","last_update_posted":"2024-04-05"},{"id":"80bbead0-defc-4564-bc2a-476e047424b7","acronym":"","url":"https://clinicaltrials.gov/study/NCT02936752","created_at":"2021-01-29T07:13:34.466Z","updated_at":"2024-07-02T16:35:13.077Z","phase":"Phase 1","brief_title":"Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating Agents","source_id_and_acronym":"NCT02936752","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Jingzhuda (entinostat)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 06/23/2017","start_date":" 06/23/2017","primary_txt":" Primary completion: 10/01/2022","primary_completion_date":" 10/01/2022","study_txt":" Completion: 03/21/2025","study_completion_date":" 03/21/2025","last_update_posted":"2024-03-25"},{"id":"5f31eade-11f2-4c8a-bd77-1e3a256fbe11","acronym":"ETCTN-9844","url":"https://clinicaltrials.gov/study/NCT02453620","created_at":"2021-01-18T11:46:08.614Z","updated_at":"2024-07-02T16:35:13.667Z","phase":"Phase 1","brief_title":"Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer","source_id_and_acronym":"NCT02453620 - ETCTN-9844","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • CD86","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2 • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Jingzhuda (entinostat) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 57","initiation":"Initiation: 02/12/2016","start_date":" 02/12/2016","primary_txt":" Primary completion: 04/22/2021","primary_completion_date":" 04/22/2021","study_txt":" Completion: 08/30/2024","study_completion_date":" 08/30/2024","last_update_posted":"2024-03-20"},{"id":"48501323-09cb-4f5b-a243-32ead55180fa","acronym":"","url":"https://clinicaltrials.gov/study/NCT05370547","created_at":"2022-05-11T15:55:57.619Z","updated_at":"2024-07-02T16:35:16.239Z","phase":"Phase 1/2","brief_title":"Chidamide Bridging for CAR-T Therapy","source_id_and_acronym":"NCT05370547","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" BCL2 • BCL6 • PMAIP1","pipe":" | ","alterations":" CD19 positive","tags":["BCL2 • BCL6 • PMAIP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Yescarta (axicabtagene ciloleucel) • Epidaza (chidamide) • fludarabine IV • Carteyva (relmacabtagene autoleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 05/25/2022","start_date":" 05/25/2022","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-03-06"},{"id":"b256a039-fd2a-468d-ac7b-e44e1e11c391","acronym":"KEPIDA-2","url":"https://clinicaltrials.gov/study/NCT05833724","created_at":"2023-04-27T14:05:13.981Z","updated_at":"2024-07-02T16:35:17.751Z","phase":"Phase 2","brief_title":"Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)","source_id_and_acronym":"NCT05833724 - KEPIDA-2","lead_sponsor":"Great Novel Therapeutics Biotech \u0026 Medicals Corporation","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive • ALK negative","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Epidaza (chidamide)"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 04/01/2024","start_date":" 04/01/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-02-26"},{"id":"10e34025-5747-4dee-b161-fb7ad52933b1","acronym":"INFORM2 NivEnt","url":"https://clinicaltrials.gov/study/NCT03838042","created_at":"2021-01-18T18:56:47.273Z","updated_at":"2024-07-02T16:35:20.359Z","phase":"Phase 1/2","brief_title":"INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies","source_id_and_acronym":"NCT03838042 - INFORM2 NivEnt","lead_sponsor":"University Hospital Heidelberg","biomarkers":" PD-L1 • TMB • MYC","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • TMB • MYC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Jingzhuda (entinostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 91","initiation":"Initiation: 05/26/2020","start_date":" 05/26/2020","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2024-02-07"},{"id":"dac5d115-7904-464c-a96a-a31864a53af9","acronym":"ABC","url":"https://clinicaltrials.gov/study/NCT06220487","created_at":"2024-01-24T16:19:51.060Z","updated_at":"2024-07-02T16:35:22.410Z","phase":"Phase 2","brief_title":"A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL","source_id_and_acronym":"NCT06220487 - ABC","lead_sponsor":"Nanfang Hospital, Southern Medical University","biomarkers":" ABL1","pipe":"","alterations":" ","tags":["ABL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Blincyto (blinatumomab) • prednisone • Epidaza (chidamide) • Nailike (olverembatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 67","initiation":"Initiation: 02/01/2024","start_date":" 02/01/2024","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2024-01-24"},{"id":"7d670f75-2f18-4cb3-9f44-0fc426b7febe","acronym":"CINDERELLA","url":"https://clinicaltrials.gov/study/NCT05464173","created_at":"2022-07-19T14:54:26.715Z","updated_at":"2024-07-02T16:35:22.701Z","phase":"Phase 1/2","brief_title":"Chidamide in Combination With Abemaciclib and Endocrinotherapy（Doctor's Choice） in Breast Cancer Patients Previously Treated With Palbociclib","source_id_and_acronym":"NCT05464173 - CINDERELLA","lead_sponsor":"Biyun Wang, MD","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Verzenio (abemaciclib) • fulvestrant • Epidaza (chidamide)"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 07/01/2022","start_date":" 07/01/2022","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-01-22"},{"id":"0fab3fc5-371c-4513-860f-4d767f471226","acronym":"","url":"https://clinicaltrials.gov/study/NCT05281276","created_at":"2022-03-16T16:55:17.375Z","updated_at":"2024-07-02T16:35:26.269Z","phase":"Phase 1","brief_title":"Chidamide + Celecoxib in Advanced Metastatic Colorectal Cancer (CCmCC)","source_id_and_acronym":"NCT05281276","lead_sponsor":"Taipei Medical University Shuang Ho Hospital","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • RAS mutation • RAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • RAS mutation • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Epidaza (chidamide) • celecoxib oral"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 09/20/2022","start_date":" 09/20/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-12-14"},{"id":"58500c01-6437-4480-ae01-c2820de938ce","acronym":"DONIMI","url":"https://clinicaltrials.gov/study/NCT04133948","created_at":"2021-01-18T20:11:28.878Z","updated_at":"2024-07-02T16:35:29.174Z","phase":"Phase 1/2","brief_title":"Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma","source_id_and_acronym":"NCT04133948 - DONIMI","lead_sponsor":"The Netherlands Cancer Institute","biomarkers":" IFNG","pipe":"","alterations":" ","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • domatinostat (4SC-202)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 01/07/2020","start_date":" 01/07/2020","primary_txt":" Primary completion: 01/11/2022","primary_completion_date":" 01/11/2022","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2023-11-15"},{"id":"1e82c7a9-fdab-4a93-b27d-b001dd636e57","acronym":"","url":"https://clinicaltrials.gov/study/NCT02718066","created_at":"2021-01-18T13:17:44.848Z","updated_at":"2024-07-02T16:35:29.778Z","phase":"Phase 1b/2","brief_title":"Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT02718066","lead_sponsor":"HUYABIO International, LLC.","biomarkers":" EGFR • PD-L1 • ALK","pipe":"","alterations":" ","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Epidaza (chidamide)"],"overall_status":"Completed","enrollment":" Enrollment 96","initiation":"Initiation: 08/01/2016","start_date":" 08/01/2016","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 09/01/2023","study_completion_date":" 09/01/2023","last_update_posted":"2023-11-09"}]